Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 6 art units • 10 examiners • 0 of 10 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Wuxi Biologics Ireland Limited currently has 10 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 10 actions are being handled by 10 distinct examiners, resulting in a direct ratio of examiners to pending matters. The prosecution activity is distributed across 6 distinct art units, showing that the company's biological and pharmaceutical filings are reviewed by several different specialized groups within the patent office.
The busiest examiner is LEUNG, CHRISTINA Y, who is responsible for 1 pending office action. This matches the workload of every other examiner involved with the portfolio, as no individual manages more than a case. With 10 distinct examiners and 6 distinct art units, the company's filings are reviewed by a diverse group of officials, preventing any single examiner from having a disproportionate impact on the overall portfolio status. Practitioners should focus on the specific technical requirements of the 6 distinct art units, as these groups will likely have more influence on prosecution outcomes than the individual examiners. The busiest examiner is responsible for 1 pending office action.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (10%) |
| §112 only | 4 (40%) |
| Double-patenting + other | 3 (30%) |
| Multi-statute (no §101) | 2 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEUNG, CHRISTINA Y | 1 | 77.4% | +1.1% |
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
| SIEFKE, SAMUEL P | 1 | 63.1% | +17.8% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| GZYBOWSKI, MICHAEL STANLEY | 1 | 68.3% | +52.0% |
| BORGEEST, CHRISTINA M | 1 | 55.6% | +21.4% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| HOWARD, ZACHARY C | 1 | 64.0% | +37.9% |
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| GUSTILO, ESTELLA M | 1 | 53.6% | +34.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19348335 | RAMAN SPECTROSCOPY INTEGRATED PERFUSION CELL CULTURE SYSTEM FOR MONITORING AND AUTO-CONTROLLING PERFUSION CELLCULTURE | LEUNG, CHRISTINA Y | — |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | VIJAYARAGHAVAN, JAGAMYA NMN | 54d |
| 18952889 | NOVEL ANTI-PD-L1 ANTIBODIES | ROONEY, NORA MAUREEN | — |
| 18702286 | SYSTEMS FOR THE EXTRACTION OF MACROMOLECULES | SIEFKE, SAMUEL P | — |
| 18692311 | D3-BINDING MOLECULES AND USES THEREOF | OUSPENSKI, ILIA I | — |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | — |
| 18272548 | POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION | BORGEEST, CHRISTINA M | — |
| 18270160 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | LU, CHENG | — |
| 18265338 | AN ANTIBODY AGAINST P-CADHERIN AND USES THEREOF | HOWARD, ZACHARY C | — |
| Art Unit | Apps |
|---|---|
| 3991 | 1 |
| 1675 | 1 |
| 1642 | 1 |
| 1674 | 1 |
| 1633 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19348335 | RAMAN SPECTROSCOPY INTEGRATED PERFUSION CELL CULTURE SYSTEM FOR MONITORING AND AUTO-CONTROLLING PERFUSION CELLCULTURE | LEUNG, CHRISTINA Y | 3991 | §103§112 | Non-Final OA | — | Pending | Oct 02, 2025 |
| 18952889 | NOVEL ANTI-PD-L1 ANTIBODIES | ROONEY, NORA MAUREEN | — | §112Other | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18702286 | SYSTEMS FOR THE EXTRACTION OF MACROMOLECULES | SIEFKE, SAMUEL P | — | §102 | Non-Final OA | — | Pending | Apr 17, 2024 |
| 18692311 | D3-BINDING MOLECULES AND USES THEREOF | OUSPENSKI, ILIA I | — | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | — | §102§103 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18272548 | POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION | BORGEEST, CHRISTINA M | 1675 | §112DP | Non-Final OA | — | Pending | Jul 14, 2023 |
| 18270160 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | LU, CHENG | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18265338 | AN ANTIBODY AGAINST P-CADHERIN AND USES THEREOF | HOWARD, ZACHARY C | 1674 | §112Other | Final Rejection | — | Pending | Jun 05, 2023 |
| 17572262 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §112Other | Final Rejection | 54d | Pending | Jan 10, 2022 |
| 17425870 | NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES | GUSTILO, ESTELLA M | 1646 | §112DP | Non-Final OA | — | Pending | Jul 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial